Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06032338
Other study ID # 2022-A01914-39
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 14, 2023
Est. completion date November 14, 2026

Study information

Verified date July 2023
Source University Hospital, Caen
Contact Lydia GUITTET, MD,PhD
Phone +33(0)231065781
Email guittet-l@chu-caen.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effect of mailing FIT with the invitation on participation and colonoscopy rates will be evaluated in a randomized controlled trial conducted in the Centre-Val de Loire (CVL) region, involving 64,000 people from the population eligible for colorectal cancer population-based organised screening program (CRC-PBOSP). In the "C" control group, invitations, test delivery and reminders will be carried out in accordance with the CRC-PBOSP rules at the time of the study. Intervention group "B" will evaluate two experimental modes of invitation with direct home mailing of the test: - Method "B1": invitation with test sent to home without prior information letter - Method "B2": information letter followed by invitation with test sent home, designed to optimize participation by first-time subjects (aged 50-51) invited to the CRC-PBOSP for the first time. Ancillary studies will focus 1/ on acceptability of this intervention (qualitative study on a few general practitioners, gastroenterologists and invitees), 2/ on social and geographical inequalities of participation on a subsample of individuals included in EXPEDIT study using ecological indices (EDI, SCALE).


Recruitment information / eligibility

Status Recruiting
Enrollment 64000
Est. completion date November 14, 2026
Est. primary completion date March 14, 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years to 74 Years
Eligibility Inclusion Criteria: - 50 to 74 years old - Resident of Centre Val de Loire French area - Eligible for CRC screening invitation within the biennal CRC-PBOSP during the inclusion period - Affiliated to the health insurance scheme Exclusion Criteria: - CRC screening exclusion criteria notified to CRCDC-CVL in a previous screening round (family or personal history of CRC/adenoma, inflammatory bowel disease) - Colonoscopy in the previous 5 years) Subjects refusing data transmission to research team will be excluded from statistical analyses.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
CRC screening invitation not including the screening test.
The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
Mailing of FIT with invitation
The invitation to CRC-PBOSP will contain the CRC screening test.
Information letter before invitation
An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.

Locations

Country Name City State
France Crcdc-Cvl Tours

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Caen Centre Régional de Coordination des Dépistages des Cancers (CRCDC) Centre Val de Loire, Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Participation to CRC screening program Rate of FIT sent to laboratory for analysis within 16 of months of invitation among invitees. 16 months after the invitation
Primary Performance of colonoscopy in FIT positive patients Rate of Colonoscopy within 6 months after positive FIT among invitees with a positive FIT 6 months after the positive FIT
Secondary Participation to CRC screening program at 24 months Rate of FIT sent to laboratory for analysis within 24 of months of invitation among invitees. 24 months after invitation
Secondary Time to screening participation Time to screening participation within 24 months of invitation among invitees 24 months after invitation
Secondary Colonoscopy in FIT positive patients, 12 months after the positive test Rate of Colonoscopy within 12 months after positive FIT among invitees with a positive FIT 12 months after the positive test
Secondary Time to colonoscopy (in FIT positive patients) Time from FIT to colonoscopy within 12 months of positive FIT among invitees with a positive FIT 12 months after the positive test
Secondary Colonoscopy findings Rate of colorectal cancer or advanced neaplasia in invitees with a positive FIT 12 months after the positive test
Secondary Participation to CRC screening program in first invitees (50-51 yrs-old) Rate of FIT sent to laboratory for analysis within 16 of months of invitation among first invitees (50-51 yrs-old) 16 months after invitation
Secondary Cost-effectiveness analysis Costs of CSC-PBOSP from invitation to colonoscopy when necessary 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A